{"id":78750,"date":"2026-09-04T15:51:01","date_gmt":"2026-09-04T07:51:01","guid":{"rendered":"https:\/\/flcube.com\/?p=78750"},"modified":"2026-09-04T15:51:02","modified_gmt":"2026-09-04T07:51:02","slug":"sino-biopharmaceuticals-gpc3-adc-tqb6426-gains-fda-ind-approval-for-advanced-malignant-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78750","title":{"rendered":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1177:HKG\">HKG: 1177<\/a>)<\/strong> announced that <strong>TQB6426<\/strong>, a national <strong>Category 1 new drug<\/strong> self-developed by its subsidiary <strong>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<\/strong>, has received <strong>investigational new drug (IND) approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>advanced malignant tumors<\/strong>. The clearance advances a first-wave <strong>GPC3-targeting antibody-drug conjugate (ADC)<\/strong> \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/td><\/tr><tr><td>Approval Type<\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td>Product<\/td><td><strong>TQB6426<\/strong><\/td><\/tr><tr><td>Drug Class<\/td><td><strong>GPC3-targeting antibody-drug conjugate (ADC)<\/strong><\/td><\/tr><tr><td>Indication<\/td><td><strong>Advanced malignant tumors<\/strong><\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Developer<\/td><td><strong>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<\/strong>, subsidiary of <strong>Sino Biopharmaceutical<\/strong><\/td><\/tr><tr><td>Next Steps<\/td><td>Initiation of U.S. clinical development program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>TQB6426<\/strong>, a <strong>GPC3-targeting antibody-drug conjugate (ADC)<\/strong> and national Category 1 new drug independently developed by <strong>Chia Tai Tianqing<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>GPC3<\/strong>, a cell-membrane glycoprotein barely expressed in normal adult tissues but highly expressed in <strong>hepatocellular carcinoma (HCC)<\/strong>, where it serves as a biomarker for clinical diagnosis<\/li>\n\n\n\n<li><strong>Target Breadth:<\/strong> GPC3 expression is also up-regulated in <strong>lung squamous cell carcinoma<\/strong>, <strong>ovarian cancer<\/strong>, and other solid tumors, positioning it as a highly promising target for targeted therapy and immunotherapy<\/li>\n\n\n\n<li><strong>Preclinical Profile:<\/strong> Demonstrated potent target-binding affinity and selective cytotoxicity against tumor cells<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Bystander killing activity and in vivo anti-tumor efficacy superior to similar candidates, indicating <strong>best-in-class (BIC) potential<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> <strong>No GPC3-targeting ADC has been approved for marketing worldwide<\/strong>, leaving a wide-open therapeutic space<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence-amp-development-outlook\" class=\"wp-block-heading\">Preclinical Evidence &amp; Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Preclinical Finding<\/th><\/tr><\/thead><tbody><tr><td>Target-binding affinity<\/td><td>Potent<\/td><\/tr><tr><td>Selective cytotoxicity<\/td><td>Demonstrated against tumor cells<\/td><\/tr><tr><td>Bystander killing activity<\/td><td>Superior to similar candidates<\/td><\/tr><tr><td>In vivo anti-tumor efficacy<\/td><td>Superior to similar candidates<\/td><\/tr><tr><td>Positioning<\/td><td>Best-in-class (BIC) potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical data position <strong>TQB6426<\/strong> ahead of peer candidates in the nascent GPC3-ADC field, with an efficacy and bystander-killing profile that supports development across GPC3-expressing solid tumors. The FDA IND clearance opens the door to first-in-human evaluation in the United States alongside the molecule\u2019s development trajectory in China.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>White-space opportunity:<\/strong> With no GPC3-targeting ADC approved anywhere in the world, <strong>TQB6426<\/strong> competes for a genuinely uncontested category rather than a crowded one<\/li>\n\n\n\n<li><strong>Large addressable market:<\/strong> <strong>Hepatocellular carcinoma<\/strong> remains one of the most prevalent and lethal cancers in China and globally, with limited effective options in advanced stages<\/li>\n\n\n\n<li><strong>Platform validation:<\/strong> The FDA acceptance validates <strong>Chia Tai Tianqing\u2019s<\/strong> in-house ADC discovery capabilities and strengthens <strong>Sino Biopharmaceutical\u2019s<\/strong> (HKG: 1177) innovation credentials<\/li>\n\n\n\n<li><strong>Global expansion:<\/strong> U.S. IND clearance marks a concrete step in the group\u2019s internationalization strategy, creating optionality for global trials and partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug development, clinical potential and market opportunity are forward-looking and subject to risks and uncertainties, including clinical trial outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302344_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090302344_c.\"><\/object><a id=\"wp-block-file--media-80291352-b121-41b3-b542-22574aed9f84\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302344_c.pdf\">2026090302344_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090302344_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-80291352-b121-41b3-b542-22574aed9f84\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,661,62,908,313],"class_list":["post-78750","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78750\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78750\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T07:51:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T07:51:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors\",\"datePublished\":\"2026-09-04T07:51:01+00:00\",\"dateModified\":\"2026-09-04T07:51:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750\"},\"wordCount\":521,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78750#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78750\",\"name\":\"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T07:51:01+00:00\",\"dateModified\":\"2026-09-04T07:51:02+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78750\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78750#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78750","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.","og_url":"https:\/\/flcube.com\/?p=78750","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T07:51:01+00:00","article_modified_time":"2026-09-04T07:51:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78750#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78750"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors","datePublished":"2026-09-04T07:51:01+00:00","dateModified":"2026-09-04T07:51:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78750"},"wordCount":521,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Chia Tai Tianqing Pharmaceutical","Clinical trial approval \/ initiation","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78750#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78750","url":"https:\/\/flcube.com\/?p=78750","name":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T07:51:01+00:00","dateModified":"2026-09-04T07:51:02+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) \u2014 a class with no approved product worldwide \u2014 into U.S. clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78750#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78750"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78750#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical\u2019s GPC3 ADC TQB6426 Gains FDA IND Approval for Advanced Malignant Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78750"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78750\/revisions"}],"predecessor-version":[{"id":78752,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78750\/revisions\/78752"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}